. Some previous studies revealed that administration of chemotherapy was often accompanied by reenergisation of the tumours, whilst in the case of certain regimens of chemotherapy and, especially, of hyperthermia, contrary effects were observed (for an overview see Steen, 1989) . The PMEs as precursors of cell membrane phospholipid synthesis generally showed a decline following chemotherapy (Lutz et al., 1988; Daly et al., 1990) . However, to our knowledge, only Evelhoch and coworkers (1987) investigated whether these changes are response-specific markers indicating significant tumour regression following chemotherapy or whether they are related to an unspecific action of chemotherapy, occurring independently of drug cytotoxicity. They studied the in vivo response of a mammary adenocarcinoma sensitive to adriamycin in comparison to a drug-resistant subline following treatment with adriamycin by 31P NMR spectroscopy. As they could not find any changes in the phosphorus metabolism in the resistant subline following chemotherapy, the 31P NMR spectroscopic effects observed in the sensitive subline were assigned as response-specific markers for chemotherapy. Moreover, Cohen et al. (1986) reported differences in the levels of phospholipids and PCr in a MCF-7 mammary carcinoma cell line resistant to adriamycin in comparison to the sensitive wild type. This result was confirmed in Evelhoch's study (1987) , 1984; Toohill et al., 1987) .
In vivo 31P NMR spectroscopy is a recently developed, clinically applicable technique that provides a non-invasive monitor of pH and phosphorus-containing metabolites which are either involved in energy metabolism, such as phosphocreatine (PCr), nucleosidetriphosphates (NTP:) and inorganic phosphorus (Pi), or in lipid metabolism, such as phosphomonoesters (PME) and phosphodiesters (PDE) (for an overview see Glickson, 1989) . Some previous studies revealed that administration of chemotherapy was often accompanied by reenergisation of the tumours, whilst in the case of certain regimens of chemotherapy and, especially, of hyperthermia, contrary effects were observed (for an overview see Steen, 1989) . The PMEs as precursors of cell membrane phospholipid synthesis generally showed a decline following chemotherapy (Lutz et al., 1988; Daly et al., 1990) . However, to our knowledge, only Evelhoch and coworkers (1987) investigated whether these changes are response-specific markers indicating significant tumour regression following chemotherapy or whether they are related to an unspecific action of chemotherapy, occurring independently of drug cytotoxicity. They studied the in vivo response of a mammary adenocarcinoma sensitive to adriamycin in comparison to a drug-resistant subline following treatment with adriamycin by 31P NMR spectroscopy. As they could not find any changes in the phosphorus metabolism in the resistant subline following chemotherapy, the 31P NMR spectroscopic effects observed in the sensitive subline were assigned as response-specific markers for chemotherapy. Moreover, Cohen et al. (1986) reported differences in the levels of phospholipids and PCr in a MCF-7 mammary carcinoma cell line resistant to adriamycin in comparison to the sensitive wild type. This result was confirmed in Evelhoch's study (1987) (Posner et al., 1984; Toohill et al., 1987) .
In the present study we investigated the phosphorus metabolism, by 31P NMR spectroscopy, in a xenografted human epidermoid carcinoma of the hypopharynx, growing subcutaneously in athymic mice, and in two sublines of the tumour with an increasing resistance to CDDP. In contrast to the above mentioned studies, the sublines exhibited only partial resistance to CDDP, which is closer to the situation observed in human patient tumours. By comparing three tumour lines with continuously decreasing sensitivity to CDDP, we expected to be able to assign the phenomena related to drug resistance regarding the initial levels of the phosphorus containing metabolites in the tumours and the alterations induced by CDDP with regard to the therapeutic efficacy. Parallel to NMR spectroscopy, tumour cytokinetics and histology were investigated in order to relate the changes observed in the 31P NMR spectra with generally accepted indicators of tumour response.
Materials and methods
Tumour system and chemotherapy The investigations were performed on a moderately differentiated carcinoma of the hypopharynx which had been established from an untreated patient. The tumour was transplanted serially in male athymic mice (NMRI, nu/nu) and passaged by implanting tumour suspensions into the flank of the animals. From this tumour which was highly sensitive to cisplatin (CDDP), two sublines with an increasing degree of resistance to the drug were selected experimentally in vivo by repeated course treatment with CDDP over several generations. The subline with the lower resistance was maintained by i.p. injections of 3.5 mg CDDP kg-' weekly, whilst the animals bearing the higher resistant subline received applications of 5.5 mg CDDP kg-' twice a week. CDDP was obtained from Strem Chemicals. Before administration, the drug was dissolved in a mixture of DMSO and saline (1/9, v/v) . For NMR experiments, the mice of the treatment groups obtained intraperitoneal injections of CDDP in doses of 4, 8 or 12 mg kg-' (0.1 ml solution 10 g-' body weight) whereas the control animals only received the vehicle medium of 0.3 ml saline containing 10% DMSO. When entered to the study the mice had an average body weight of 31.2 ± 1.5 g. Tumour volumes were estimated by caliper measurement according to the formula for the volume of ellipsoids (0.5 x length x width2).
The surviving fraction of tumour cells following chemotherapy treatment was calculated according to the formula (Corbett & Valeriote, 1987) The other halves of the divided tumours which had been removed at certain intervals after application of CDDP or the vehicle medium only were prepared for flow cytometry. These tumour specimens were gathered and frozen in liquid nitrogen for 1 to 30 days. Following defrosting, the tumours were minced mechanically and enzymatically in a pepsinhydrochloride solution (0.2% HC1, 3,500 U 1-pepsin) for 8 min at 37C. The cell suspensions were then centrifuged at 1,300 r.p.m. for 8 min and resuspended in 70% ethanol. After another centrifugation, the pellets were resuspended in a solution containing 10 mg 1' ethidium bromide and 10 mM MgCl2 in 0.1 M tris buffer (pH 7.5) in such a manner that final concentrations of 1-2 x 106 cells per ml were attained. To eliminate unspecific staining reactions due to RNA, the cell suspensions were incubated with ribonuclease, added in a final concentration of 10 g ml', for 30 min at 30°C. The flow-cytometric measurements were performed with an Epics 752 cytometer (Coulter Electronics Co.) equipped with an argon laser (wavelength 488 nm).
Results

Tumour strains
Though the resistant strains Hyp 1/H and Hyp I/R represent sublines of the CDDP-sensitive Hypl, they all differ from one another in many respects. The doubling time of tumour volume amounted to 13 days in Hyp 1, 10 days in Hypl/H, and 8 days in Hyp I/R. Moreover, the tumours were characterised by different histological patterns. Whereas the tumours of the original sensitive strain Hyp 1 consisted of tumour cell clusters with a broad peripheral border of densely packed, viable cells and small central areas filled up with necrotic cells, the tumour cell border was loosened in the moderately and highly resistant strains Hyp 1/H and Hyp I/R, included numerous enlarged extracellular spaces, and consisted of reticularly arranged tumour cell cords (Figures 5a, 6a) . Only in large resistant tumours, centrally located necroses were detectable. Small, capillary-conducting strands of connective tissue surrounded the tumour cell aggregates, being separated from them by a basal lamina which was often multilayered in the sensitive tumour line Hyp 1, but monolayered in both resistant strains. In all three tumour lines, the tumour cells were large, roundish cells with a clear nucleus including a prominent, compact nucleolus and a cytoplasm with numerous ribosomes, but few other organelles (Figure 7a, b) . Figure 1 illustrates an example of a 3'P NMR spectrum of an individual Hyp 1 tumour. The average metabolic characteristics and the tumour volumes of the three tumour lines before substance application are given in Table I (the data presented include both treatment and control groups). The semi-resistant strain Hyp 1/H differed from the drug-sensitive Hyp 1 with regard to the PME/a-NTP and P-NTP/a-NTP ratios with a confidence value of P <0.05. The highly resistant strain Hyp 1/R, however, did not show any statistically significant differences from Hyp 1.
Uninfluenced tumour growth
Figures 2-4 show the changes occurring in the metabolite ratios PCr/Pi and PME/PDE and the pH of the three tumour Figure 2 Sensitive strain Hyp 1 (number of animals; 0 mg kg-1: n = 8; 4 mg kg-1: n = 6; 8 mg kg-1: n = 10; 12 mg kg-1: n = 15). Figure 3 Moderately resistant strain Hyp 1/H (number of animals; 0mg kg-'; n = 6; 4mg kg-': n = 5; 8mg kg-': n = 6; 12 mg kg-': n = 6). Figure 4 Highly resistant strain Hyp I/R (number of animals; 0 mg kg-': n = 7; 4 mg kg-': n = 6; 8 mg kg-': n = 6; 12 mg kg-': n = 13). Legend for a: -0mg CDDP kg-', --4 mg CDDP kg-,. 8 mg CDDP kg-',---12 mg CDDP kg Legend for b and c: -pH-change, PME/PDE, -PCr/Pi.
2b,c). The pH increased by 0.15 units after 12 mg CDDP kg-', this alteration, however, being not significant (n = 6). In contrast to the metabolic changes observable in Hyp 1, the PME/PDE value markedly increased in the 12 mg kg-' treatment group between days 3 and 10 after treatment. The non-responsive group, treated with 4 mg CDDP kg-', finally, showed changes similar to those observable in untreated tumours.
Morphologically, no remarkable alterations were detectable in histological and semi-thick sections of the semiresistant strain following application of 4 mg CDDP kg-' ( Figure  Sb ). Only at the ultrastructural level, many nucleoli appeared loosened and showed the signs of gradual segregation of the nucleolar components between days 2 to 10 ( Figure 7,c,d ). In the case of the medium dose of 8 mg CDDP kg-', the histological and electronmicroscopical specimens revealed necrotisaton of single cells or cell groups within the peripheral border of vital tumour cells on day 3 (Figure 7c ). This development manifested by the condensation of the nucleolar chromatin, segmentation of the nuclei, segregation of the nucleolar components, and the appearance of large secondary lysosomes and glycogen inclusions in the cytoplasm between days 2 to 6. The tumour tissue loosened as consequence of the enlargement of intercellular spaces. From day 1 after substance application, the capillaries in the strands of connective tissue were widened and filled with crowds of blood cells. Beginning on day 6, the number of structurally damaged and necrotic cells again decreased and normal morphology restored by day 8. When the highest dose of 12 mg CDDP kg-' was administered to the animals bearing Hyp 1/H, the mentioned cytological and histological alterations developed in the tumours more rapidly and more severely. On day 3, only plaque-like residues of comparably intact tumour tissue were detectable (Figue 5a). macrophages had invaded the xenografts and phagocytosed necrotic tumour cells. On day 6, first signs of ongoing recovery were remarkable leading to a gradual reconstruction of tumour cell clusters with only small areas of central necrosis during the following 4 days. A similar dose dependence also manifested in the DNA histograms of the Hyp 1/H tumours. When they were treated with 4 mg CDDP kg-', no pronounced cell cycle alterations were observable (Figure 8 ). Following application of the highest dose of 12 mg CDDP kg-', a remarkable portion of cells were arrested at the G0/S boundary during the first 3 days, then traversed through the S phase on days 4 and 5 and reached the G2 phase on day 6, provoking there a pronounced G2 block which continuously dissolved during the following 2 days. Additionally, numerous cells were highly damaged on day 3 and disintegrated to cellular and nuclear fragments which appeared in the histograms at low DNA values as a peak increasing exponentially to zero. Moreover, a third symmetrical peak grew up on the left of the G0 population of the tumour cells (Figure 8 ). This peak represents mouse connective tissue cells such as macrophages and fibroblasts, which immigrated into the xenografts of human tumours, differing from human tumour cells by a lower DNA content and a lower number of chromosomes. All these phenomena were reversible within several days, thus leading to a normalisation of the histograms on day 10. In the case of the medium dose of 8 mg CDDP kg-', a moderate cell arrest in the early S phase developed within 1 day. This cell population progressed synchronously through the mid and the late S phase during the following 48 h, and attained the G2 phase on day 5 and induced there a moderate G2 block on days 5 and 6, which gradually dissolved within the following 2 days (data not shown).
Highly resistant strain Hyp J/R In the resistant tumour line Hyp 1/R, finally, the lower CDDP doses (4 and 8 mg kg-') did not effect any significant retardation of tumour growth, whereas 12 mg CDDP kg-' induced a growth delay of 5 days, however, without causing mentionable reduction of the tumour volume (Figure 4a) . Accordingly, no significant metabolic changes occurred in the 31P NMR spectrum with none of the CDDP doses applied. Only in the case of the high CDDP dose, the data on day 3 indicate a trend (Figure 4b ) similar to that seen in the responsive tumours of Hyp 1 (Figure 2b) and Hyp 1/H (Figure 3b ). When tumour regrowth happened on day 5 and later, the metabolic alterations which developed were comparable to those observed in tumours during uninfluenced growth (Figure 4c ). In the Hyp I/R tumours treated with 4 or 8 mg CDDP kg-' the changes in metabolism paralleled those of the untreated tumour during the whole posttherapeutic period (Figure 4b,c) .
Regarding the morphological alterations, no effects were detectable in the Hyp 1/R tumours following application of of developing tumour cell necroses slightly increased on days 2 to 6 after application of CDDP (Figure 6d ), the strength of structural damages resembling those of Hyp 1/H tumours after treatment with 8 mg CDDP kg-'. On day 8 and later, the Hyp I/R tumours had again normalised and no longer showed any peculiar features in comparison to untreated control tumours. In correspondence to these morphological results, the cytokinetic investigations confirmed that neither 4 nor 8 mg CDDP kg-' were able to disturb the cell progression. In the case of the highest dose of 12 mg kg-' a G2 block appeared 4 days after substance application as the only observable finding. Discussion Cohen and coworkers (1986) were the first investigators who reported on differences in the levels of phosphate metabolites in a MCF-7 mammary carcinoma cell line resistant to adriamycin in comparison to the corresponding sensitive tumour cell line. In the latter, the relative spectral conribution of phosphocreatine was reduced, whereas the concentrations of the PME and PDE were elevated. Evelhoch et al. (1987) confirmed these results in a 3'P NMR study for the phospholipids in the murine mammary adenocarcinoma Mamm 17/A sensitive to adriamycin and the resistant subline Mamm 17/Adr growing in C3H/He mice. In the present study on the Hyp 1 squamous cell carcinoma, which was highly sensitive to CDDP, and its sublines Hyp 1/H and Hyp 1/R, which were characterised by increasing levels of resistance to CDDP, these results could not be verified, Hyp 1/H contained higher levels of PCr and PME than Hyp 1, but the confidence values of these differences were low (Table I) . Hyp 1/R which was more resistant to CDDP than Hyp 1/H, did not show analogous differences. As CDDP exerts its cytoxicity by producing intrastrand crosslinks in DNA strands (Sundquist & Lippard, 1990) , whilst adriamycin intercalates between neighbouring DNA bases (Muller, 1975) , the mechanisms of induced drug resistance are different. In the case of CDDP increased resistance of tumour cells was shown to result often from a higher cellular efficiency in excising Pt-DNA adducts (Masuda et al., 1988 , Eastman & Schulte, 1988 Sekiya et al., 1989) , whereas in cells resistant to adriamycin an enhanced capacity for drug transport out of the cells was supposed to be the main mechanism responsible for drug resistance (Inaka et al., 1979; Cowan et al., 1986) . it is conceivable that this property of adriamycin-resistant cells is associated with alterations in membrane metabolism and, thus, could explain the decreased concentrations of the PMEs and PDEs, which are both metabolites of membrane-bound phospholipids (for an overview see Van den Bosch, 1974; Cohen, 1988) .
In a '3C NMR study, Lyon et al. (1988) found that the adriamycin-resistant MCF-7 cancer cell line had developed an enhanced glycolysis rate compared to the sensitive cell line. This was explained by increased energy requirement associated with drug efflux and detoxification and would be consistent with the finding of a higher PCr level in the adriamycin-resistant cell line. However, neither in Evelhoch's investigations (1987) nor in the present study, this result could be confirmed for the resistant tumour lines. It is known that, in murine and xenotransplanted tumours, the PCr ratio is especially sensitive to the histological architecture of the tumour (Evelhoch et al., 1986; Vaupel et al., 1989) , thus possibly obscuring differences in the energy demand of a tumour on the cellular level. This explanation is additionally confirmed by the observation that the resistant sublines of Hyp 1 used in the present study actually differed in their histological appearance from the original sensitive tumour.
Regarding the 3'P NMR spectral changes in the tumour lines following chemotherapy with CDDP, the results obtained indicate that the most sensitive and earliest marker predictive for tumour response is the PME/PDE ratio. The decrease in the level of this ratio is mainly due to a decrease in the PME level. In tumours the main contribution to this resonance comes from the phospholipids phosphorylethanolamine and phosphorylcholine (Cohen et al., 1986) . They are synthesised by the enzymatic activity of ethanolamine and choline kinases which catalise the first step of phospholipid biosynthesis in vivo (Van den Bosch, 1974) . Increased levels of PMEs have been hypothesised to be associated with intensified cell membrane synthesis and cell proliferation (Maris et al., 1985; Sostman et al., 1988) . The decline in the PME contents after therapy in the well responding tumours confirms this hypothesis.
A re-energisation occurred in responding tumours, which was reflected by an elevation of the PCr/Pi ratio. This increase was mainly due to an elevated PCr concentration in the tumour. It is unlikely, however, that this phenomenon would be the result of an increased signal contribution from the body wall because the volume of the tumours hardly decreased during the first 3 days after substance application.
In addition, the pH increased, this change being statistically significant only in the sensitive tumour line Hyp 1 after application of the high dose of CDDP. The extent of all alterations were clearly related to the degree of tumour response documented by regressions of the tumour volume and severe cytotoxic lesions in the tumour tissue. Thus, they provide response-specific markers of sensitivity to CDDP and do obviously not represent effects of CDDP on tumour metabolism which are not related to the cytotoxicity of the drug. This result is confirmed by the fact that, in the sensitive tumour Hyp 1, a dose of 4mg CDDP kg-', resulting in a growth delay of about 20 days, induced more pronounced changes in the 31P NMR spectrum than a dose of 12 mg CDDP kg-' in the highly resistant strain Hyp I/R (growth delay only 5 days). Sijens et al. (1987) reported an alkaline shift in a immunocytoma resistant to CDDP following application of a subtherapeutic dose of 1 mg CDDP kg-'. The mechanism inducing the pH change in this tumour does apparently not work in the epidermoid carcinoma sublines Hyp 1/H and Hyp 1/R, where the comparably high dose of 12 mg CDDP kg-' did not provoke any effect on the pH level.
According to the equation given by Corbett and Valeriote (1987) (cf. Materials and methods), a dose of 12 mg CDDP kg-' would induce a cell killing of 25% cells in the highly resistant strain Hyp 1/R, 62% in the semiresistant line Hyp 1/H, and 78% in the sensitive strain Hyp 1. This means that the 31P NMR spectroscopy would be insensitive to rates of cell killing at the level of 30%. Regarding the histological sections, however, they did not confirm the development of substantial cellular necroses in Hyp I/R tumours following treatment with 12 mg CDDP kg-'. That is to say that, in the case of CDDP doses which only induce short-lasting growth delays, but no tumour regression, the formula for the estimation of cell killing obviously leads to wrong results.
The only cytokinetic phenomenon observed in Hyp I/R tumours was a G2 block, which dissolved on days 4 to 5 after chemotherapy, allowing the cells to restart proliferation. In contrast, treatment of the Hyp 1/H and Hyp 1 strains with 12 mg CDDP kg-' primarily resulted in a cell arrest at the GI/S boundary which was clearly associated with severe cytoxicity at the histological level (Jiickel & K6pf-Maier, 1990) . As this block dissolved earlier in the semi-resistant tumour Hyp 1/H, the cells reached the G2 and M phases sooner than in the sensitive wild type. As a consequence, tumour regrowth occurred earlier in Hyp 1/H than in Hyp 1 (Figures 2a and 3a) . This process was accompanied by an increase of the PME/PDE ratio on day 10 in Hyp 1/H compared to day 3 (Figure 3b,c) . This increase was mainly due to an elevated PME concentration in the tumour, rendering this metabolite to be a sensitive marker of both tumour regression and tumour regrowth.
The histological sections revealed widened capillaries on day 1 after chemotherapy and enlarged extracellular spaces in responding tumours, the first necrotic cells being detectable on day 3 after chemotherapy. In accordance with the 31P NMR-spectral changes, these alterations were more pronounced in the sensitive tumour Hyp 1 than in the semi-resistant Hyp 1/H or in the highly resistant Hyp I/R. Following application of CDDP doses which hardly induced any growth delay of the treated tumours (4 mg CDDP kg-' in Hyp 1/R and Hyp 1/H), the histological and semi-thick sections did not reveal any morphological changes. Ultrastructurally, however the nucleoli within these tumours appeared loosened and showed the signs of segregation of the nucleolar components. Interestingly, these phenomena did not exhibit any detectable changes in the 31P NMR spectrum.
Summarising the histological and cytokinetic data, they provide evidence that actually only those tumour cell alterations, which are related to cytotoxic effects and finally culminate in tumour cell dying, are correlated with profound metabolic changes observable in the phosphorus NMR.
